| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -27.7 | -20.1 |
| EPS (diluted, $ a share) | $-0.36 | $-0.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ELVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Enliven Therapeutics, Inc.: key numbers
- Share price
- $46.85Close, Nov 17
- Market cap
- $3.45B
- Shares outstanding
- 73.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Enliven Therapeutics, Inc.
All →Enliven Therapeutics Financial Results
Enliven Therapeutics reported third quarter 2026 financial results and announced alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib. The company ended the quarter with $884.4 million in cash and marketable securities, providing a projected cash runway into 2030.
“This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial.”
Rick Fair, Chief Executive Officer of Enliven
“As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program.”
Rick Fair, Chief Executive Officer of Enliven
Enliven Therapeutics CFO Benjamin Hohl Sells $232K of Stock
Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $38.48 a share, worth $232K in total on Oct 19, 2026. Shares held after the trade: 38,000 (-13.7%).
- Value
- $232K
- Shares
- 6,018
- Price
- $38.48
- Role
- CFO
- Holding change
- -13.7%
- Trade date
- Oct 19, 2026
Enliven Therapeutics CMO Helen Louise Collins Sells $192K of Stock
Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $38.47 a share, worth $192K in total on Oct 19, 2026. Shares held after the trade: 25,000 (-16.7%).
- Value
- $192K
- Shares
- 5,000
- Price
- $38.47
- Role
- CMO
- Holding change
- -16.7%
- Trade date
- Oct 19, 2026
Enliven Therapeutics Leadership Change
Enliven Therapeutics appointed Kristine Ball to its Board of Directors and Audit Committee, effective October 14, 2026. Ms. Ball, an experienced biopharmaceutical executive, joins as the company prepares to initiate a pivotal Phase 3 trial for relcobatinib. Her compensation includes $55,000 in annual cash fees and stock options valued at approximately $650,000.
- Counterparty
- Kristine Ball
Enliven Therapeutics Director J. Scott Garland Sells $607K of Stock
J. Scott Garland, Director, sold 13,000 shares of Enliven Therapeutics, Inc. at $46.67 a share, worth $607K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $607K
- Shares
- 13,000
- Price
- $46.67
- Role
- Director
- Holding change
- -100.0%
- Trade date
- Oct 1, 2026
Enliven Therapeutics CFO Benjamin Hohl Sells $303K of Stock
Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $50.03 to $51.49 a share (average $50.35) in 3 transactions, worth $303K in total on Sep 17, 2026. Shares held after the trade: 38,000 (-0.8%).
- Value
- $303K
- Shares
- 6,018
- Average price
- $50.35
- Role
- CFO
- Holding change
- -0.8%
- Trade date
- Sep 17, 2026